Navigation Links
CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCyte's Glycoprotein Products in Heart Attack Disease Model
Date:6/3/2008

BOTHELL, Wash., June 3 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) has selected the Cardiovascular Phenotyping Core at Washington University School of Medicine in St. Louis to perform a study to further evaluate CellCyte's glycoprotein products. The goal of the study is to investigate the efficiency of CellCyte's glycoprotein products in a preclinical model of myocardial infarction (heart attack).

"We look forward to working with the scientific team at Washington University on this study, which will continue to advance the research and development efforts for our glycoprotein products," noted Ronald W. Berninger, Ph.D., Chief Scientific Officer at CellCyte. "These are highly experienced researchers, as demonstrated by the fact that they perform more than 6,000 surgical and imaging procedures annually. Outsourcing a portion of the preclinical work allows us to move our program forward more quickly and is complementary to our in-house scientific efforts," Berninger added.

About the Washington University School of Medicine

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's Hospitals. The School of Medicine is one of the leading medical research, teaching, and patient care institutions in the nation, currently ranked third in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's Hospitals, the School of Medicine is linked to BJC HealthCare.

About CellCyte Genetics

CellCyte Genetics is a biotechnology company engaged in the discovery, development and commercialization of stem cell enabling therapeutic products. CellCyte is developing products to allow more efficient delivery and increased retention of adult stem cells to diseased organs, such as the heart. The goal of these therapies is to increase the number of stem cells delivered to a damaged organ, thereby markedly increasing organ healing and functional restoration. The Company's lead product in development, CCG-TH30, is designed to send autologous bone marrow-derived (adult) stem cells to the heart of patients after a heart attack.

CellCyte Genetics | 1725 220th Street SE | Bothell | Washington | 98021 | USA

For further information see: http://www.cellcyte.com.

Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

Safe Harbor Statement

THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE RESEARCH AND DEVELOPMENT OF CCG- TH30. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS AND COMPANIES AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS, AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS, OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME TO TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE COMPANY'S MOST RECENT REPORTS ON FORM 10-KSB AND FORM 10-Q. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE.


'/>"/>
SOURCE CellCyte Genetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
2. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
3. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
4. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
5. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
6. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
7. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
8. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
9. Genetics Determine Optimal Drug Dose of Common Anticoagulant
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... offering. ... is very strong with a total of 97 drug candidates. Pharma giant ... are involved in the development of the IPF therapeutics. The IPF pipeline ... stage, 15 are in Phase II stage, 12 are in Phase I ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... to prep patients for colonoscopy at the HyGIeaCare® Center that is to be ... FL. , The HyGIeaCare® Prep, cleared by the U.S. Food and ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... Time GPS”: a dauntless and enlightened study of the second-coming of Christ, and ... published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation as ... ninety-one, he shares the Wisdom God bestowed upon him in this publication. , ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... of inspiring stories about real people of God in congregations across the United ... Miller, a Presbyterian minister ordained in 1964 who has served congregations in seven ...
(Date:3/23/2017)... Greensboro, NC & Seattle, WA (PRWEB) , ... March 23, 2017 ... ... international public health emergency and now estimates that there could be four million Zika-related ... fastest growing epidemics to date with numbers of US cases reported per year skyrocketing ...
Breaking Medicine News(10 mins):